© 1999 by European Society of Cardiology
Copyright © 1999, European Society of Cardiology
Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide
Department of Internal Medicine, University Hospital Maastricht, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands
* Corresponding author. Tel.: +31-43-387-7005; fax: +31-43-387-5006 BHO{at}sint.azm.nl
Objective: The aim of the present study was to determine the vasoactive effects of brain natriuretic peptide (BNP) as compared to those of atrial natriuretic peptide (ANP) in normal man. Methods: Ten healthy male subjects (median age 21 (20–23) year) were studied twice. In the first study equimolar doses (1, 3, and 10 pmol/dl/min) of both BNP and ANP (in random order and double blind) were infused into the brachial artery of the non-dominant arm with a 1-h wash-out period in between. In the second study two BNP (n=5) or ANP (n=5) dose–response curves were performed in order to assess the repeatability of the BNP/ANP infusions. To this end, BNP and ANP were infused in the same equimolar doses as in the first protocol. Forearm blood flow (FBF) was determined by venous occlusion plethysmography before and during infusions. Results: BNP increased the FBF ratio (infused/contralateral arm) by 6%, 17%, and 48%, respectively (p<0.05), while ANP increased the FBF ratio by 4%, 58%, and 133% (p<0.001). The slopes of the BNP dose–response curves differed significantly from those of the ANP curves (18.1 versus 43.2; p=0.022). No differences were observed between the repeated dose–response curves of either BNP or ANP. Conclusions: The present data demonstrate that BNP induces a dose-dependent vasodilatation in man. On a molar basis, however, this vasodilatation is significantly less than the vasodilatation induced by ANP. These differences may be related to differences in natriuretic-peptide-receptor affinity. Furthermore, our data show that the vasoactive effects of both BNP and ANP are repeatable in time.
KEYWORDS Natriuretic peptide; Blood flow; Hemodynamics; Vasoconstriction/dilation; Hormones
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
B. Freestone, F. Gustafsson, A. Y. Chong, P. Corell, C. Kistorp, P. Hildebrandt, and G. Y. H. Lip Influence of Atrial Fibrillation on Plasma Von Willebrand Factor, Soluble E-Selectin, and N-Terminal Pro B-type Natriuretic Peptide Levels in Systolic Heart Failure Chest, May 1, 2008; 133(5): 1203 - 1208. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kathiresan, P. Gona, M. G. Larson, D. Levy, C. Newton-Cheh, T. J. Wang, E. J. Benjamin, R. S. Vasan, J. A. Vita, G. F. Mitchell, et al. Response to Letter Regarding Article, "Cross-Sectional Relations of Multiple Biomarkers From Distinct Biological Pathways to Brachial Artery Endothelial Function" Circulation, September 5, 2006; 114(10): e384 - e384. [Full Text] [PDF] |
||||
![]() |
R. S Garcha and A. D Hughes CNP, but not ANP or BNP, Relax Human Isolated Subcutaneous Resistance Arteries by an Action Involving Cyclic GMP and BKCa Channels Journal of Renin-Angiotensin-Aldosterone System, June 1, 2006; 7(2): 87 - 91. [Abstract] [PDF] |
||||
![]() |
M. E. Wilhide and W. K. Jones Potential Therapeutic Gene for the Treatment of Ischemic Disease: Ad2/Hypoxia-Inducible Factor-1{alpha} (HIF-1)/VP16 Enhances B-Type Natriuretic Peptide Gene Expression via a HIF-1-Responsive Element Mol. Pharmacol., June 1, 2006; 69(6): 1773 - 1778. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kathiresan, P. Gona, M. G. Larson, J. A. Vita, G. F. Mitchell, G. H. Tofler, D. Levy, C. Newton-Cheh, T. J. Wang, E. J. Benjamin, et al. Cross-Sectional Relations of Multiple Biomarkers From Distinct Biological Pathways to Brachial Artery Endothelial Function Circulation, February 21, 2006; 113(7): 938 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L.M. Cruden, K. A.A. Fox, C. A. Ludlam, N. R. Johnston, and D. E. Newby Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition Hypertension, December 1, 2004; 44(6): 913 - 918. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Komarek, A. Bernheim, R. Schindler, R. Steden, W. Kiowski, and H. P. B.-L. Rocca Vascular Effects of Natriuretic Peptides in Healthy Men Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 263 - 270. [Abstract] [PDF] |
||||
![]() |
A. Y. Chong, A. D. Blann, J. Patel, B. Freestone, E. Hughes, and G. Y.H. Lip Endothelial Dysfunction and Damage in Congestive Heart Failure: Relation of Flow-Mediated Dilation to Circulating Endothelial Cells, Plasma Indexes of Endothelial Damage, and Brain Natriuretic Peptide Circulation, September 28, 2004; 110(13): 1794 - 1798. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schmitt, A. Qasem, C. McEniery, I. B. Wilkinson, V. Tatarinoff, K. Noble, J. Klemes, N. Payne, M. P. Frenneaux, J. Cockcroft, et al. Role of natriuretic peptides in regulation of conduit artery distensibility Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1167 - H1171. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kuhn Structure, Regulation, and Function of Mammalian Membrane Guanylyl Cyclase Receptors, With a Focus on Guanylyl Cyclase-A Circ. Res., October 17, 2003; 93(8): 700 - 709. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schmitt, A. J.M. Broadley, A. K. Nightingale, N. Payne, P. Gunaruwan, J. Taylor, L. Lee, J. Cockcroft, A. D. Struthers, and M. P. Frenneaux Atrial Natriuretic Peptide Regulates Regional Vascular Volume and Venous Tone in Humans Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1833 - 1838. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. van der Zander, A. J.H.M. Houben, A. A. Kroon, T. K.A. Wierema, M. J.M.J. Fuss-Lejeune, D. Koster, and P. W. de Leeuw Does Brain Natriuretic Peptide Have a Direct Renal Effect in Human Hypertensives? Hypertension, January 1, 2003; 41(1): 119 - 123. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Militello Role of Nesiritide in Decompensated Heart Failure Journal of Pharmacy Practice, August 1, 2002; 15(4): 326 - 333. [Abstract] [PDF] |
||||









